Blog

Months after a monstrous blowup, a closely watched biotech sets its sights on gene therapy – STAT


STAT

Months after a monstrous blowup, a closely watched biotech sets its sights on gene therapy
STAT
The pivot to gene therapy is a chance for Ramaswamy, Axovant's chairman, to write a second act for his neuroscience company. Cheruvu said the Oxford BioMedica deal represents “a strategic shift” for the company, an effort “to push Axovant in the
Axovant Licenses Investigational Gene Therapy for Parkinson's Disease from Oxford BioMedica and Announces Key …GlobeNewswire (press release)


Axovant pivots with new gene therapy, Spark co-founder as CTOFierceBiotech

all 11 news articles »

2018-06-06 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.